Proteomics Core Facility

蛋白质组学核心设施 蛋白质组学核心致力于为癌症中心的研究人员提供出色的基于质谱的服务和培训。该核心提供了最先进的分析，用于从蛋白质混合物中鉴定蛋白质;定义翻译后修饰（即磷酸化，乙酰化，泛素化）;以及使用SILAC和Doppler等方法定量分析蛋白质表达或修饰的变化。 ITRAQ，核心与研究人员合作，以确保使用最好的蛋白质组学应用程序来设计回答重要的癌症生物学相关问题所需的实验方案，并为学生和研究员提供独特的培训环境。核心支持的蛋白质组学研究的亮点包括《细胞》（Salmon）、《自然》（Zhang）、《美国国家科学院院刊》（PNAS）和《分子和细胞生物学》（Burridge， Marzluff，Patterson）.核心由三位博士领衔。我们的团队由三位具有丰富蛋白质组学经验的科学家组成：Lee Graves博士（系主任）、Maria Hines（设施主任）和Xian Chen（技术开发主任）。 核心的使用稳步增加，反映了理解蛋白质组动态的基本需要，在不断增加的复杂程度。该机构和癌症中心在过去五年中为新的质谱仪和纳米LC仪器提供了超过250万美元。该核心继续提高其执行高通量大规模定量蛋白质组学的能力。为了实现这些目标，CCSG支持144，563美元，这大约是2010年预计蛋白质组学核心运营成本的30%。2009年，46个癌症中心成员（100%同行评审）使用了该核心，占核心使用总量的86%。拟议预算将部分支持6名核心人员的薪金和质谱仪的服务合同。这是一个大约19%的CCSG支持，需要大规模的高通量，定量蛋白质组学的扩展。未来的计划包括扩展基于质谱的基础设施，增加一个LTQ Orbitrap，以支持最先进的定量蛋白质组学。

Proteomics Core Facility The Proteomics Core strives to provide outstanding mass spectrometry-based service and training to Cancer Center researchers. The core provides state-of-the-art analysis for protein identification from mixtures of proteins; defining post-translational modifications (i.e. phosphorylation, acetylation, ubiquitination); and quantitative analysis of changes in protein expression or modification using methods such as SILAC and ITRAQ, The core works with investigators to ensure use of the best proteomic applications for design of experimental protocols needed to answer important cancer biology-related questions and provides a unique training environment for students and fellows. Highlights of proteomic research supported by the core include papers In Cell (Salmon), Nature (Zhang), PNAS (Whang) and Molecular and Cellular Biology (Burridge, Marzluff, Patterson). The core is led by three Ph.D. scientists with extensive proteomics experience: Drs. Lee Graves (Faculty Director), Maria Hines (Facility Director) and Xian Chen (Technology Development Director). Core usage has steadily increased and reflects the fundamental need to understand proteome dynamics at an ever increasing level of sophistication. The Institution and Cancer Center has provided more than $2.5 million dollars in the past five years for new mass spectrometry and nano-LC instrumentation. The core continues to increase its capacity to perform high-throughput large scale, quantitative proteomics. To accomplish these objectives, CCSG support of $144,563 is proposed, which is approximately 30% of the projected Proteomics Core operating costs for 2010. In 2009, the core was used by 46 cancer center members (100% peer-reviewed), accounting for 86% of total core usage. The proposed budget will partially support salaries of six core personnel and sen/ice contracts for mass spectrometers. This is an approximate 19% increase in CCSG support that is needed for the expansion of large scale high-throughput, quantitative proteomics. Future plans involve expanding the mass spectrometry-based infrastructure with an additional LTQ Orbitrap for support of state-of-the-art quantitative proteomics.